Drug utilisation and evaluation of adjuvant therapy in mild to severe asthma patients

Asian Journal of Pharmaceutical and Clinical Research

Volumn 5, Issue 2, 2012, Pages 151-154

  Arunshirwaikar, A ^a   Premkumar, N ^b   Sarala, A ^b   Bhaskaran, K ^b   Rajagopal, P L ^c  

^a GULF MEDICAL UNIVERSITY   (United Arab Emirates)

^b Pariyaram Medical College   (India)

^c Academy of Pharmaceutical Sciences   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; MONTELUKAST; THEOPHYLLINE;

ADD ON THERAPY; ADJUVANT THERAPY; ADULT; ARTICLE; ASTHMA; CLINICAL EVALUATION; COMBINATION CHEMOTHERAPY; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG TOLERABILITY; DRUG UTILIZATION; FEMALE; FOLLOW UP; HUMAN; INDIA; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; QUALITY OF LIFE; SCORING SYSTEM; TERTIARY HEALTH CARE; TREATMENT OUTCOME;

EID: 84875461787     PISSN: 09742441     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Reiss TF, Chervinsky P, Dockhorn RJ, Shingo S, Seidenberg B, Edwards TB. Montelukast, a once daily leukotriene receptor antagonist in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Arch Intern Med 1998;158:1213-1220.
2. Robinson et al., receiving high-dose inhaled corticosteroids. Am i Respir Crit Core Med2001;i 62:578-85.
3. Walsh L, Wong C, Cooper 5, et aL Morbidity from asthma in relation to regular treatment: a community based study. Thorax
4. British Thoracic Society/Scottish lmtercollegiete Guideline Network (SI'S/SIGN). British guideline and management of asthma. Tharax 2003SB(Suppl I):i 1-94.
5. National Institutes of Health. Highli9hts of the Expert Panel Report II: Guidelines far the diagnosis and management of asthma. NIH publication no. 97-4051. Bethesda, MD:National Institutes of Health, 1 997.
6. National Institutes of Health, NationalHeart, 'ung and Blood Institute. Global initiative for asthma. Global strategy for asthma management and preventian. Publication no. 95-3659. Bethesda, MD:NHLBI/WHO Workshop Report, 1995.
7. Scottish Intercollegiate Guideline Network (SIGN). SIGN 50: a guideline developer'shandbook. SIGN publication no. 50. Edinburgh: SIGN 2002.
8. Vaquerizo Mi, Casan P Castillo J, et al Effect af montelukast added to inhaled budesonide on control of mild to moderate asthma. Thorax 2003;58:204-10.
9. Price DB, Hernandez D, Magyar P et al Randomised controlled trial of Montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Tharax 2003;58:21 1-6.
10. Laviolotte M, Malrnstrom K, Lu 5, et aL Mantelukast added to inhaled beclomethasone in treatment of asthma, Am J Respir Crit Care Med 1999;i 60:1862-8.
11. Ldfdahl C-G, Reiss TF, Loll JA, at oL Randomised, placebo controlled trial of effect of a leukotriene-receptor antagonist, montelukast, on tapering inhaled carticosteroids in asthmatic patients. BMI1999;319:87-90
12. Tohda V Fujimuri M, Taniguchi H, eta?. Leukotriene receptor antagonist, montelukast, can reduce the need for inhaled steroid while maintaining the clinical stability of asthmatic patients. Clin Exp Allergy 2002;32:1 180-6.
13. Virchaw JC, Prosse A, Noya I, etal. Zalirlukast improves asthma control in patients
14. Ducharme F, Hicks G, Kokuma R. Addition of onti-leukotriene agents compared to inhaled corticosteroids for chronic asthma (Cochrone Review). In: The Cachrane Library. Issue 1. Oxford: Update Software 2002.
15. Busse N, Nelson H Wolfe J, eta1, Comparison of inho(ed salmeterol and oral zofirlukost in patients with asthma. J Allergy C?in lmmuno? 1999;103:1075-80.
16. Nelson HS, Busse WW, Kerwin E, eta1, Fluticasone propionate/salmeteral combination provides more effective asthma control than low dose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol.2000;106:1088-95
17. Manning PJ, Watson RM, Margolskee DJ, Williams VC, Schwartz JI, O'Byrne PM. Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4-receptor antagonist. N Engl J Med 1990;323:1736-173
18. Bronsky EA, Kemp JP, Zhang J, Guerreiro D, Reiss TF. Dose-related protection of exercise bronchoconstriction by montelukast, a cysteinyl leukotriene-receptor antagonist, at the end of a once-daily dosing interval. Clin Pharmacol Therapeutics1997;62:556-561.